Cargando…
An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments
Targeted therapies are playing an increasing role in oncology. Among them, particular attention is nowadays reserved to histology-agnostic treatments. Rare molecular alterations affecting different neoplastic forms, such as Microsatellite Instability (MSI), Neurotropic Tyrosine Receptor Kinase (NTRK...
Autores principales: | Marchetti, Antonio, Di Lorito, Alessia, Felicioni, Lara, Buttitta, Fiamma |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916754/ https://www.ncbi.nlm.nih.gov/pubmed/31857850 http://dx.doi.org/10.18632/oncotarget.27343 |
Ejemplares similares
-
NTRK gene fusions in solid tumors: agnostic relevance, prevalence and diagnostic strategies
por: Marchetti, Antonio, et al.
Publicado: (2022) -
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: a new algorithm for patient selection and personalized treatment
por: Buttitta, Fiamma, et al.
Publicado: (2020) -
BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report
por: Buttitta, Fiamma, et al.
Publicado: (2023) -
Mutational Profile of GNAQ
(Q209) in Human Tumors
por: Lamba, Simona, et al.
Publicado: (2009) -
Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations
por: Marchetti, Antonio, et al.
Publicado: (2022)